Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2022 | 3 |
2023 | 2 |
2024 | 1 |
Search Results
5 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial.
Lancet Haematol. 2023 Jan;10(1):e46-e58. doi: 10.1016/S2352-3026(22)00292-7. Epub 2022 Nov 10.
Lancet Haematol. 2023.
PMID: 36370742
Clinical Trial.
Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial.
de la Fuente MI, Colman H, Rosenthal M, Van Tine BA, Levacic D, Walbert T, Gan HK, Vieito M, Milhem MM, Lipford K, Forsyth S, Guichard SM, Mikhailov Y, Sedkov A, Brevard J, Kelly PF, Mohamed H, Monga V.
de la Fuente MI, et al. Among authors: forsyth s.
Neuro Oncol. 2023 Jan 5;25(1):146-156. doi: 10.1093/neuonc/noac139.
Neuro Oncol. 2023.
PMID: 35639513
Free PMC article.
Clinical Trial.
Item in Clipboard
Etavopivat, a Pyruvate Kinase Activator in Red Blood Cells, for the Treatment of Sickle Cell Disease.
Schroeder P, Fulzele K, Forsyth S, Ribadeneira MD, Guichard S, Wilker E, Marshall CG, Drake A, Fessler R, Konstantinidis DG, Seu KG, Kalfa TA.
Schroeder P, et al. Among authors: forsyth s.
J Pharmacol Exp Ther. 2022 Mar;380(3):210-219. doi: 10.1124/jpet.121.000743. Epub 2022 Jan 14.
J Pharmacol Exp Ther. 2022.
PMID: 35031585
Item in Clipboard
Safety, Pharmacokinetics, and Pharmacodynamics of Etavopivat (FT-4202), an Allosteric Activator of Pyruvate Kinase-R, in Healthy Adults: A Randomized, Placebo-Controlled, Double-Blind, First-in-Human Phase 1 Trial.
Forsyth S, Schroeder P, Geib J, Vrishabhendra L, Konstantinidis DG, LaSalvia K, Ribadeneira MD, Wu E, Kelly P, Kalfa TA.
Forsyth S, et al.
Clin Pharmacol Drug Dev. 2022 May;11(5):654-665. doi: 10.1002/cpdd.1058. Epub 2022 Jan 12.
Clin Pharmacol Drug Dev. 2022.
PMID: 35019238
Free PMC article.
Clinical Trial.
Item in Clipboard
Multicenter, phase 1 study of etavopivat (FT-4202) treatment for up to 12 weeks in patients with sickle cell disease.
Saraf SL, Hagar RW, Idowu M, Osunkwo I, Cruz K, Kuypers FA, Brown RC, Geib J, Ribadeneira MD, Schroeder P, Wu E, Forsyth S, Kelly PF, Kalfa TA, Telen MJ.
Saraf SL, et al. Among authors: forsyth s.
Blood Adv. 2024 Apr 19:bloodadvances.2023012467. doi: 10.1182/bloodadvances.2023012467. Online ahead of print.
Blood Adv. 2024.
PMID: 38640200
Item in Clipboard
Cite
Cite